What Actually Happens When You Take Wegovy

The decision most people face: is what I am feeling normal, or a sign something is wrong?

That question comes up repeatedly among people starting Wegovy, and it is the right one to sit with. The first few weeks tend to be the most eventful. Semaglutide slows gastric emptying (food moves through your stomach more slowly) and signals to appetite centres in the brain that you have had enough. Both effects are deliberate and therapeutic. But they also mean that nausea, a quieter appetite than you expected, and occasional digestive discomfort are not signs of failure. They are, for most people, the medicine working as designed.

The misconception worth clearing up gently: many people expect to feel better the moment they inject. The reality is that the first pen is an adjustment phase. Your system is meeting a new hormone signal, and the 0.25 mg starting dose is specifically chosen to reduce the severity of that transition, not to produce weight loss immediately. Knowing this upfront changes how you read the first few weeks.

The Wegovy treatment overview at nume covers how the full titration pathway is managed, including what our prescribers look for before each dose step.

What happens week by week as the dose increases

Most people titrate from 0.25 mg through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, spending roughly four weeks at each level, and our page on what to expect at the Wegovy 1 mg dose goes into more detail on that particular step. At each step, the effects on appetite tend to deepen. Hunger between meals becomes less insistent. Portion sizes that used to feel necessary start to feel like too much. This is not a conscious effort, the medicine shifts the baseline.

Gastrointestinal effects are most pronounced in the first week or two after each dose increase, then typically ease. Nausea, loose stools, constipation, reflux and burping are the most reported, as documented on the NHS semaglutide medicines page. Fatigue and mild headache are also reported, particularly early on, and some people notice shivers on Wegovy, especially in the first day or two after injecting. For a small number of people, these effects are significant enough to stay at a lower dose longer, or to stop. That is a clinical decision made with a prescriber, not something to push through without support.

People who experience persistent, severe stomach pain that radiates to the back should seek urgent medical attention, this symptom can indicate pancreatitis, which the MHRA has flagged as a rare but serious risk with GLP-1 medicines. You can report any suspected side effects, including unexpected reactions, through the MHRA Yellow Card scheme.

Digestive side effects like trapped wind are a specific source of discomfort for some, and if bloating and gas are particularly troublesome our page on managing trapped wind on Wegovy has practical guidance on managing it alongside the more general advice on trapped gas on Wegovy.

What happens to weight over the first six months

The STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo in adults with obesity) reported an average weight reduction of around 15% in the treatment group, published in the New England Journal of Medicine. That figure is a mean across thousands of participants; individual results varied. Some people see notable change by week eight; others find the first two months slower and the middle period more significant. Neither pattern means the medicine is not working, response timelines differ by person, starting weight and adherence to lifestyle changes alongside treatment.

NICE's appraisal of Wegovy notes that if less than 5% weight loss has occurred after six months at the maintenance dose, continuing should be reviewed. That is a useful checkpoint to be aware of, not a countdown clock to panic about in month two.

For people thinking about what Wegovy costs privately (and what a single transparent price actually includes) the weight-loss treatments page sets out how our pricing works.

What happens if you stop Wegovy, and what that means for your decision now

This is the part of the picture that deserves honest attention. Semaglutide does not produce permanent changes to appetite regulation on its own. When the medicine is stopped, hunger signals tend to return toward their pre-treatment level over weeks to months, and weight often returns with them if lifestyle foundations have not been built during treatment. This is not a flaw specific to Wegovy, it reflects how the body responds to the removal of a hormone-level signal. Long-term studies following participants after discontinuation confirm it is a consistent pattern.

What that means practically: the period on treatment is the opportunity to establish eating habits, activity patterns and a relationship with food that persist beyond it. Our clinical team treats the medicine as one part of a broader picture, not the whole of it. The prescriber discussion at the start of treatment is the right moment to talk through what you are trying to achieve and over what timescale, so that the decision to continue, step down or stop is planned rather than reactive.

People considering semaglutide for the first time sometimes find it useful to read about how semaglutide works as background before a consultation, and our frequently asked questions covers many of the practical questions people have once they have decided to go ahead.